Sort   by:  
 Page size 
TranscriptomicsPredicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial
PURPOSE: Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant TOP trial, in which patients with estrogen receptor (ER)-negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to ev...
ORGANISM(S): Homo sapiens 
2010-01-26 | E-GEOD-16446 | biostudies-arrayexpress
TranscriptomicsTumor expression data from neoadjuvant trial of cisplatin monotherapy in triple negative breast cancer patients
Evidence suggests that BRCA1 mutation associated tumors have increased sensitivity to DNA damaging agents like cisplatin. Sporadic triple negative breast cancers (TNBC) have many phenotypic similarities to BRCA1 tumors and may have a similar sensitivity to cisplatin. We tested the efficacy of cisp...
ORGANISM(S): Homo sapiens 
2009-11-04 | E-GEOD-18864 | biostudies-arrayexpress
Sort   by:  
 Page size